Stock Events

Stock Events

Vallon Pharmaceuticals 

$0.4
48
-$0.06-13.04% Friday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
5.1M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

8MayExpected
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
-0.46
-0.34
-0.21
-0.09
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
0Revenue
-7.02MNet Income

Analyst Ratings

$40.00Average Price Target
The highest estimate is 40.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VLON. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm that competes in developing innovative therapeutics in areas similar to GRI Bio, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences operates in the biopharmaceutical sector focusing on antiviral drugs, directly competing with GRI Bio's research and development in similar therapeutic areas.
Biogen
BIIB
Mkt Cap22.63B
Biogen is known for its research in neurological diseases, potentially overlapping with GRI Bio's focus areas, hence a competitor.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on creating drugs for complex diseases, which might intersect with GRI Bio's target diseases, making them competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, directly competing with GRI Bio in the development of innovative treatments.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA technology, which could be used in similar therapeutic areas as GRI Bio, positioning it as a competitor.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, a novel approach that could compete with GRI Bio's drug development strategies.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on rare genetic diseases, potentially competing with GRI Bio if they target similar conditions.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad range of products that could compete across multiple areas with GRI Bio's portfolio.

About

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Show more...
CEO
Employees
3
Country
US
ISIN
US92023M1018

Listings

XNAS
US
GRI
BOATS
BOATS
GRI.BOATS

0 Comments

Share your thoughts

FAQ

What is Vallon Pharmaceuticals stock price today?▼
The current price of VLON is $0.4 USD — it has decreased by -13.04% in the past 24 hours. Watch Vallon Pharmaceuticals stock price performance more closely on the chart.
What is Vallon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vallon Pharmaceuticals stocks are traded under the ticker VLON.
What is Vallon Pharmaceuticals market cap?▼
Today Vallon Pharmaceuticals has the market capitalization of 5.1M
What is Vallon Pharmaceuticals revenue for the last year?▼
Vallon Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Vallon Pharmaceuticals net income for the last year?▼
VLON net income for the last year is -7.02M USD.
How many employees does Vallon Pharmaceuticals have?▼
As of April 02, 2026, the company has 3 employees.
In which sector is Vallon Pharmaceuticals located?▼
Vallon Pharmaceuticals operates in the Manufacturing sector.
When did Vallon Pharmaceuticals complete a stock split?▼
The last stock split for Vallon Pharmaceuticals was on April 24, 2023 with a ratio of 1:30.